HUTCHMED DRC

NASDAQ: HCM (HUTCHMED (China) Limited)

Kemas kini terakhir: 13 jam lalu

13.41

0.01 (0.07%)

  • 1H 0.07%
  • 5H -0.52%
  • 1B -11.07%
  • 6B -20.88%
  • Tahun Ke Tarikh -11.07%
  • 1T -29.97%
  • 5T -36.78%
Penutupan Terdahulu 13.40
Buka 13.53
Jumlah Dagangan 49,129
Purata Dagangan (3B) 92,615
Modal Pasaran 2,292,801,536
Harga / Pendapatan (P/E TTM) 67.05
Harga / Pendapatan (P/E Ke hadapan) 47.85
Harga / Jualan (P/S) 4.24
Harga / Buku (P/B) 3.43
Julat 52 Minggu
11.51 (-14%) — 21.50 (60%)
Tarikh Pendapatan 29 Jul 2025 - 4 Aug 2025
Margin Keuntungan 5.99%
Margin Operasi (TTM) -4.99%
EPS Cair (TTM) 0.200
Pertumbuhan Hasil Suku Tahunan (YOY) 6.40%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -84.70%
Jumlah Hutang/Ekuiti (D/E MRQ) 11.64%
Nisbah Semasa (MRQ) 2.83
Aliran Tunai Operasi (OCF TTM) -46.98 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -50.75 M
Pulangan Atas Aset (ROA TTM) -2.14%
Pulangan Atas Ekuiti (ROE TTM) 5.04%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Menurun Bercampur
Drug Manufacturers - Specialty & Generic (Global) Menurun Bercampur
Stok HUTCHMED (China) Limited Bercampur Menurun

AISkor Stockmoo

-0.4
Konsensus Penganalisis -2.0
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal -2.5
Purata -0.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
HCM 2 B - 67.05 3.43
UTHR 14 B - 12.62 2.04
VTRS 10 B 5.58% - 0.550
NBIX 12 B - 40.88 4.74
LNTH 6 B - 15.19 6.42
ALVO 3 B - - -

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Mid Value
% Dimiliki oleh Orang Dalam 0.12%
% Dimiliki oleh Institusi 4.03%

Pemilikan

Nama Tarikh Syer Dipegang
Schroder Investment Management Group 31 Mar 2025 2,843,513
Allianz Asset Management Gmbh 31 Mar 2025 1,004,539
Aia Group Ltd 31 Mar 2025 315,439
M&G Plc 31 Mar 2025 258,693
Catalyst Funds Management Pty Ltd 31 Mar 2025 139,748
Xy Capital Ltd 31 Mar 2025 113,136
Hennion & Walsh Asset Management, Inc. 31 Mar 2025 48,769

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
22 May 2025 Pengumuman HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
23 Apr 2025 Pengumuman HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
21 Apr 2025 Pengumuman HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China
21 Mar 2025 Pengumuman HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
20 Mar 2025 Pengumuman Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
19 Mar 2025 Pengumuman HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
19 Mar 2025 Pengumuman HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
18 Mar 2025 Pengumuman Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China
18 Mar 2025 Pengumuman HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
06 Mar 2025 Pengumuman HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
05 Mar 2025 Pengumuman HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
Papar semua
14.3414.3413.8413.8413.3513.3512.8612.8612.3612.36May 15May 15May 16May 16May 19May 19May 20May 20May 21May 21May 22May 22May 23May 23May 27May 27

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
-0.000-0.000-0.100-0.100-0.200-0.200-0.300-0.300-0.400-0.400MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda